- €49.21bn
- €48.90bn
- €7.74bn
European shares mixed as US strikes on Iran fuel Mideast escalation fears (updated)
UCB rises after MS upgrade to 'overweight'
Europe Research Roundup: Berkeley Group, Diageo, Yara
Brief: UCB Announces New Biologics Manufacturing Facility In U.S.
Brief: UCB Says Its DZP Shows 'Efficacy' Across Multiple Clinical Endpoints
Brief: UCB's BIMZELX 3-Year Data Shows Lasting Efficacy In Psoriatic Arthritis, Axial Spondyloarthritis
Brief: UCB, Domino Data Lab Collaborate To Modernize Statistical Computing Environment In Life Sciences
Brief: UCB's Rystiggo Receives Approval In Japan For Two New Administration Methods
European healthcare drops as Trump says tariffs on sector coming soon
European healthcare drops as Trump says tariffs on sector coming soon
European pharma stocks fall ahead of Trump's 'Liberation Day'
Brief: UCB Presents New Data On Investigational Therapy For Thymidine Kinase 2 Deficiency
Incyte falls after late-stage data from experimental skin disease drug
Incyte falls after late-stage data from experimental skin disease drug
Brief: Bimzelx Two-Year Data At AAD Showed Potential To Eliminate Draining Tunnels In Hidradenitis Suppurativa
Brief: UCB FY Revenue Up At 6.15 Bln
Brief: UCB FY Revenue EUR 6,150 Million Vs. IBES Estimate EUR 5,807 Million
Earnings Poll: Ucb SA full year results due on February 27
Brief: UCB's BIMZELX Demonstrates Sustained Disease Control In Hidradenitis Suppurativa